Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 Septiembre 2023 - 7:30AM
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of pathologic mineralization and intimal proliferation,
today announced Douglas A. Treco, Ph.D., the company’s chief
executive officer and chairman of the board, will present at the
H.C. Wainwright 25th Annual Global Investment Conference on Monday,
September 11, 2023, from 12:00-12:30pm ET.
A live webcast of the presentation can be
accessed from the Investor Relations section of Inozyme’s
website under events, where a replay of the event will also be
available for a limited time.
About Inozyme Pharma
Inozyme Pharma, Inc. is a clinical-stage rare
disease biopharmaceutical company developing novel therapeutics for
the treatment of diseases impacting the vasculature, soft tissue
and skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical trials for the
treatment of ENPP1 Deficiency and ABCC6 Deficiency.For more
information, please visit www.inozyme.com and follow us
on LinkedIn, X (formerly Twitter), and Facebook.
ContactsInvestors:Inozyme PharmaStefan Riley,
Director of IR and Corporate Communications(857)
330-8871stefan.riley@inozyme.comMedia:SmithSolveMatt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Inozyme Pharma (NASDAQ:INZY)
Gráfica de Acción Histórica
De May 2023 a May 2024